



WE IMPROVE

people's lives by transforming
tomorrow's treatments!

AFYX is a **specialty pharmaceutical/ biopharmaceutical** company with focus on reformulation and repurposing of pharmaceuticals. Established in 2024 through a merger of Lionhearth ApS, Inphena ApS and AFYX Therapeutics A/S

Dr. Claus J. Møller-San Pedro is the Company CEO. Dr. Møller co-founded and secured successful IPOs of 3 companies in the BioPharma Industry (OXiGENE, Inc. (OTLC), I Genmab A/S (GMAB) and Y-mAbs Therapeutics, Inc (YMAB))

OUR FOCUS IS

OBSTETRICS • NICHE ONCOLOGY • PAIN AND ADDICTION





DR. OLE BAADSGAARD

(BOD, Chairman)

"Dr. Baadsgaard holds a MD degree from University of Aarhus and a DMSc degree from University of Copenhagen.. Dr. Baadsgaard has previously been Chief Medical Officer in Both Genmab A/S and Y-mAbs Therapeutics, Inc. He has been an external Expert advisor to Bank Invest Biotech in their advisory Board and co-founder of Genmab A/S. He has been lead author or contributor to more than 100 peer-reviewed journal publications and author on more than 20 patents and pending patent applications."



DR. CLAUS MØLLER-SAN PEDRO

(CEO, BOD Member)

Dr. Møller has his MD & PhD degrees from Copenhagen University. Dr. Møller is the Founder and CEO of our company. Previously Dr. Møller was Co-Founder and CEO of Y-mAbs, Inc, Before this Dr. Møller was the CEO of Azanta A/S that was later sold to Norgine as well as being a Co-Founder and EVP & COO at Genmab and instrumental in its IPO. Dr. Møller also held a position as EVP & COO in Oxigene Inc



MS. PIA LAURSEN

(BOD, Member & SVP Marketing & Logistics)

Ms Laursen brings +20 years of international experience as a strategic Manager and part of Executive Management, with focus on strategy, optimization and development of business models as well as sales and marketing strategies in LCG, B2B, B2C. Ms Laursen is an experienced BOD and brings significant commercial and marketing expertise to our board.



MR. SØREN KJÆR

(Working BOD Member)

Mr. Kjær brings +30 years of banking experience to our BOD – His background includes Venture Capital Investments and Board Positions in Life Science and Venture Capital companies. Capital raising and acquisitions. Responsible for all aspects of the change process in a Bank back-to-front in motion as well as having been CEO of Quintet Bank Luxembourg.

OBSTETRICS

Gefena (misoprostol)

For induction of labor

In development for EU and US - MAA
EU in 19 countries Feb. 2024 – US NDA
Q4 2026

Obstetric Lubricant

For facilitation of delivery – CE marked
medical device – on the market

ONCOLOGY

Nimox (nimorazole)

A hypoxic radio-sensitizer

On the market in Denmark & Norway
(Special license product)

Rivelin patch

With chemo for oral cancer and
leukoplakia and steroid for ulcerations

Entering clinical tests Q4 2024

PAIN AND ADDICTION

S-ketamine Nasal

Nasal spray for cluster headache in
Phase II clinical development

Diamorphine

On the market in Denmark and Norway

Buprenorphine

Tablets and film from USA & Austria –
partner sales in MENA

SUMMARY

AFYX is a specialty biopharmaceutical company

Established in 2024 through a merger of Lionhearth ApS, Inphena ApS and Afyx Therapeutics A/S

AFYX has commercial sales in the Nordics and plan to expand to the rest of the world

The Company pipeline has 8 development programs

Founded by very experienced experts from the industry

Well financed for continued build out of commercial and research activities

Planned launch of our new obstetric product in 20 EU markets in 2025 – our 3rd commercial product

OUR FOCUS IS

OBSTETRICS · NICHE ONCOLOGY · PAIN AND ADDICTION



”THE LITTLE BIG PHARMA”

THANK YOU!